Cargando…

CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities

Administration of in vitro expanded mesenchymal stromal cells (MSCs) represents a promising therapy for regenerative medicine and autoimmunity. Both mouse and human MSCs ameliorate autoimmune disease in syn-, allo- and xenogeneic settings. However, MSC preparations are heterogeneous which impairs th...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Per, Carrillo-Gálvez, Ana Belén, García-Pérez, Angélica, Cobo, Marién, Martín, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790740/
https://www.ncbi.nlm.nih.gov/pubmed/24124603
http://dx.doi.org/10.1371/journal.pone.0076979
_version_ 1782286637209747456
author Anderson, Per
Carrillo-Gálvez, Ana Belén
García-Pérez, Angélica
Cobo, Marién
Martín, Francisco
author_facet Anderson, Per
Carrillo-Gálvez, Ana Belén
García-Pérez, Angélica
Cobo, Marién
Martín, Francisco
author_sort Anderson, Per
collection PubMed
description Administration of in vitro expanded mesenchymal stromal cells (MSCs) represents a promising therapy for regenerative medicine and autoimmunity. Both mouse and human MSCs ameliorate autoimmune disease in syn-, allo- and xenogeneic settings. However, MSC preparations are heterogeneous which impairs their therapeutic efficacy and endorses variability between experiments. This heterogeneity has also been a main hurdle in translating experimental MSC data from mouse models to human patients. The objective of the present manuscript has been to further characterize murine MSCs (mMSCs) with the aim of designing more efficient and specific MSC-based therapies. We have found that mMSCs are heterogeneous for endoglin (CD105) expression and that this heterogeneity is not due to different stages of MSC differentiation. CD105 is induced on a subpopulation of mMSCs early upon in vitro culture giving rise to CD105(+) and CD105(-) MSCs. CD105(+) and CD105(-) mMSCs represent independent subpopulations that maintain their properties upon several passages. CD105 expression on CD105(+) mMSCs was affected by passage number and cell confluency while CD105(-) mMSCs remained negative. The CD105(+) and CD105(-) mMSC subpopulations had similar growth potential and expressed almost identical mMSC markers (CD29(+)CD44(+)Sca1 (+) MHC-I(+) and CD45(-)CD11b(-)CD31(-)) but varied in their differentiation and immunoregulatory properties. Interestingly, CD105(-) mMSCs were more prone to differentiate into adipocytes and osteocytes and suppressed the proliferation of CD4(+) T cells more efficiently compared to CD105(+) mMSCs. Based on these studies we propose to redefine the phenotype of mMSCs based on CD105 expression.
format Online
Article
Text
id pubmed-3790740
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37907402013-10-11 CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities Anderson, Per Carrillo-Gálvez, Ana Belén García-Pérez, Angélica Cobo, Marién Martín, Francisco PLoS One Research Article Administration of in vitro expanded mesenchymal stromal cells (MSCs) represents a promising therapy for regenerative medicine and autoimmunity. Both mouse and human MSCs ameliorate autoimmune disease in syn-, allo- and xenogeneic settings. However, MSC preparations are heterogeneous which impairs their therapeutic efficacy and endorses variability between experiments. This heterogeneity has also been a main hurdle in translating experimental MSC data from mouse models to human patients. The objective of the present manuscript has been to further characterize murine MSCs (mMSCs) with the aim of designing more efficient and specific MSC-based therapies. We have found that mMSCs are heterogeneous for endoglin (CD105) expression and that this heterogeneity is not due to different stages of MSC differentiation. CD105 is induced on a subpopulation of mMSCs early upon in vitro culture giving rise to CD105(+) and CD105(-) MSCs. CD105(+) and CD105(-) mMSCs represent independent subpopulations that maintain their properties upon several passages. CD105 expression on CD105(+) mMSCs was affected by passage number and cell confluency while CD105(-) mMSCs remained negative. The CD105(+) and CD105(-) mMSC subpopulations had similar growth potential and expressed almost identical mMSC markers (CD29(+)CD44(+)Sca1 (+) MHC-I(+) and CD45(-)CD11b(-)CD31(-)) but varied in their differentiation and immunoregulatory properties. Interestingly, CD105(-) mMSCs were more prone to differentiate into adipocytes and osteocytes and suppressed the proliferation of CD4(+) T cells more efficiently compared to CD105(+) mMSCs. Based on these studies we propose to redefine the phenotype of mMSCs based on CD105 expression. Public Library of Science 2013-10-04 /pmc/articles/PMC3790740/ /pubmed/24124603 http://dx.doi.org/10.1371/journal.pone.0076979 Text en © 2013 Anderson et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Anderson, Per
Carrillo-Gálvez, Ana Belén
García-Pérez, Angélica
Cobo, Marién
Martín, Francisco
CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities
title CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities
title_full CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities
title_fullStr CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities
title_full_unstemmed CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities
title_short CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities
title_sort cd105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790740/
https://www.ncbi.nlm.nih.gov/pubmed/24124603
http://dx.doi.org/10.1371/journal.pone.0076979
work_keys_str_mv AT andersonper cd105endoglinnegativemurinemesenchymalstromalcellsdefineanewmultipotentsubpopulationwithdistinctdifferentiationandimmunomodulatorycapacities
AT carrillogalvezanabelen cd105endoglinnegativemurinemesenchymalstromalcellsdefineanewmultipotentsubpopulationwithdistinctdifferentiationandimmunomodulatorycapacities
AT garciaperezangelica cd105endoglinnegativemurinemesenchymalstromalcellsdefineanewmultipotentsubpopulationwithdistinctdifferentiationandimmunomodulatorycapacities
AT cobomarien cd105endoglinnegativemurinemesenchymalstromalcellsdefineanewmultipotentsubpopulationwithdistinctdifferentiationandimmunomodulatorycapacities
AT martinfrancisco cd105endoglinnegativemurinemesenchymalstromalcellsdefineanewmultipotentsubpopulationwithdistinctdifferentiationandimmunomodulatorycapacities